Cognitive impairment in psychotic illness: prevalence, profile of impairment developmental course, and treatment considerations

被引：164

作者：

McCleery, Amanda ^{[1
,2
]}

Nuechterlein, Keith H. ^{[1
,3
]}

机构：

[1] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Room 27-444, Los Angeles, CA 90095 USA

[2] VA Greater Los Angeles, VISN 22 MIRECC, Los Angeles, CA USA

[3] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA

来源：

DIALOGUES IN CLINICAL NEUROSCIENCE | 2019年 / 21卷 / 03期

关键词：

psychosis; schizophrenia; clinical high risk; affective psychosis; cognition; cognitive impairment; neurodevelopmental model; cognitive enhancement; pharmaceutical agent; cognitive training; exercise; tDCS; NEUROPSYCHOLOGICAL PERFORMANCE; 1ST-EPISODE SCHIZOPHRENIA; CLINICAL-TRIALS; 1ST EPISODE; BATTERY; METAANALYSIS; REMEDIATION; DEFICITS; NEUROCOGNITION; PRECURSORS;

D O I：

10.31887/DCNS.2019.21.3/amccleery

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations, delusions), functional outcomes for people with psychotic disorders are often disappointing. Although it is not included in the diagnostic criteria for psychotic disorders, cognitive impairment is one of the strongest determinants of community functioning in this clinical population, and thus it is an important target for intervention. In this review, we discuss the major areas of research regarding impaired cognition in psychotic illness. The specific topics covered include: (i) the prevalence of cognitive impairment in psychotic disorders; (ii) the profile and magnitude of cognitive impairment in psychotic disorders; (iii) the developmental course of cognitive impairment; (iv) the longitudinal stability of cognitive impairment; and (v) treatment approaches to improve cognitive performance in people with psychotic disorders. (C) 2019, AICH - Servier Group

引用

页码：239 / 248

页数：10

共 78 条

[1] A consideration of neuropsychologically normal schizophrenia [J].